Drug Trial Radar · NCT05132582
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
654
Actual
Start
Mar 7, 2022
Primary completion
Sep 5, 2025
Study completion Sep 28, 2027
Sponsor
- Lead sponsor
- Seagen, a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
Conditions
- HER2 Positive Breast Cancer
Interventions
TucatinibDrug
300mg given by mouth (orally) twice daily
TrastuzumabDrug
6mg/kg given into the vein (IV; intravenously) or 600mg injected under the skin (SC; subcutaneous) every 21 days
PertuzumabDrug
420mg given by IV every 21 days
Combination product: Trastuzumab + PertuzumabDrug
600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase will be given by subcutaneous injection every 21 days. May be given in place of trastuzumab and pertuzumab individually.
PlaceboDrug
Given orally twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1Time frame: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Locations
307 sites in 23 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Mayo Clinic
Scottsdale, Arizona
Central Arkansas Radiation Therapy Institute Inc d.b.a CARTI
Little Rock, Arkansas
UCLA Hematology/Oncology - Beverly Hills
Beverly Hills, California
UCLA Hematology/Oncology - Burbank
Burbank, California
UCSD Medical Center - Encinitas
Encinitas, California
Sulpizio Cardiovascular Center at UC San Diego Health
La Jolla, California
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Pavilion)
La Jolla, California
UCSD Koman Family Outpatient Pavilion
La Jolla, California
UCSD Perlman Medical Offices
La Jolla, California
UC San Diego Moores Cancer Center
La Jolla, California
UCLA Hematology/Oncology - Laguna Hills
Laguna Hills, California
Administrative Address: UCLA Hematology/Oncology
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
UCSD Medical Center - Bankers Hill
San Diego, California
UC San Diego Medical Center - Hillcrest
San Diego, California
UCLA Hematology/Oncology - San Luis Obispo
San Luis Obispo, California
UCLA Hematology/Oncology- Santa Barbara
Santa Barbara, California
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California
UCLA Hematology/Oncology Parkside
Santa Monica, California
Clinical And Translational Research Center
Torrance, California
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Harbor-UCLA Medical Center
Torrance, California
UCLA Hematology/Oncology - Santa Clarita
Valencia, California
UCSD Medical Center - Vista
Vista, California
UCLA Hematology/Oncology- Westlake
Westlake Village, California
AdventHealth Altamonte Infusion Center
Altamonte Springs, Florida
AdventHealth Medical Group Altamonte(second location)
Altamonte Springs, Florida
AdventHealth Medical Group Altamonte
Altamonte Springs, Florida
Mayo Clinic Florida
Jacksonville, Florida
AdventHealth Medical Group Orlando
Orlando, Florida
AdventHealth Orlando Infusion Center
Orlando, Florida
Emory University Hospital Midtown
Atlanta, Georgia
Emory University Clinic
Atlanta, Georgia
Winship Cancer Institute
Atlanta, Georgia
Emory Saint Joseph's Hospital
Atlanta, Georgia
University of Illinois Hospital and Health Systems (Investigational Drug Pharmacy)
Chicago, Illinois
University of Illinois Hospital and Health Systems (Outpatient Cancer Center)
Chicago, Illinois
University of Illinois Hospital and Health Systems
Chicago, Illinois
Norton Cancer Institute - Downtown
Louisville, Kentucky
Showing 40 of 307 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.